BR112018007356A2 - métodos de produção de formas fucosiladas e não fucosiladas de uma proteína - Google Patents
métodos de produção de formas fucosiladas e não fucosiladas de uma proteínaInfo
- Publication number
- BR112018007356A2 BR112018007356A2 BR112018007356A BR112018007356A BR112018007356A2 BR 112018007356 A2 BR112018007356 A2 BR 112018007356A2 BR 112018007356 A BR112018007356 A BR 112018007356A BR 112018007356 A BR112018007356 A BR 112018007356A BR 112018007356 A2 BR112018007356 A2 BR 112018007356A2
- Authority
- BR
- Brazil
- Prior art keywords
- fucosylated
- protein
- methods
- producing
- forms
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01271—GDP-L-fucose synthase (1.1.1.271)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/01—Hydro-lyases (4.2.1)
- C12Y402/01047—GDP-mannose 4,6-dehydratase (4.2.1.47), i.e. GMD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Reproductive Health (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562249828P | 2015-11-02 | 2015-11-02 | |
| US201662338280P | 2016-05-18 | 2016-05-18 | |
| PCT/US2016/059922 WO2017079165A1 (en) | 2015-11-02 | 2016-11-01 | Methods of making fucosylated and afucosylated forms of a protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018007356A2 true BR112018007356A2 (pt) | 2018-10-23 |
Family
ID=57326491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018007356A BR112018007356A2 (pt) | 2015-11-02 | 2016-11-01 | métodos de produção de formas fucosiladas e não fucosiladas de uma proteína |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10975168B2 (enExample) |
| EP (2) | EP3371206B1 (enExample) |
| JP (1) | JP6983772B2 (enExample) |
| KR (2) | KR20250051156A (enExample) |
| CN (2) | CN108431026B (enExample) |
| AU (2) | AU2016350732A1 (enExample) |
| BR (1) | BR112018007356A2 (enExample) |
| CA (1) | CA2999047A1 (enExample) |
| ES (1) | ES2875274T3 (enExample) |
| IL (1) | IL258161B2 (enExample) |
| MX (1) | MX2018004831A (enExample) |
| PL (1) | PL3371206T3 (enExample) |
| SG (2) | SG10202103875WA (enExample) |
| WO (1) | WO2017079165A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018004831A (es) | 2015-11-02 | 2018-08-01 | Genentech Inc | Metodos para confeccionar formas fucosiladas y afucosiladas de una proteina. |
| JP6674028B2 (ja) * | 2016-01-06 | 2020-04-01 | アウトルック セラピューティクス，インコーポレイティド | モノクローナル抗体組成物中のアフコシル化種の調節 |
| CN110945028B (zh) | 2017-07-10 | 2023-09-08 | 国际药物发展生物技术公司 | 用非岩藻糖基化促凋亡抗cd19抗体与抗cd20抗体或化疗剂联合治疗b细胞恶性肿瘤 |
| SG11202009216YA (en) * | 2018-03-26 | 2020-10-29 | Amgen Inc | Total afucosylated glycoforms of antibodies produced in cell culture |
| MX2020013036A (es) | 2018-06-05 | 2021-02-26 | Amgen Inc | Modulacion de la fagocitosis celular dependiente de anticuerpos. |
| MY197429A (en) * | 2018-08-29 | 2023-06-16 | United Biopharma Inc | Afucosylated antibodies and manufacture thereof |
| US20220033511A1 (en) | 2018-09-11 | 2022-02-03 | Amgen Inc. | Methods of modulating antibody-dependent cell-mediated cytotoxicity |
| HU231514B1 (hu) | 2018-11-07 | 2024-07-28 | Richter Gedeon Nyrt. | Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer |
| MX2021011330A (es) | 2019-03-20 | 2021-12-10 | Univ California | Anticuerpos de claudina-6 y conjugados de fármacos. |
| JP7682797B2 (ja) | 2019-03-20 | 2025-05-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | クローディン６二重特異性抗体 |
| BR112021022202A2 (pt) | 2019-05-06 | 2021-12-28 | Amgen Inc | Modulação de funções efetoras de anticorpo |
| KR20220069982A (ko) * | 2019-09-26 | 2022-05-27 | 암젠 인크 | 항체 조성물의 생산 방법 |
| EP4041773A1 (en) * | 2019-10-11 | 2022-08-17 | Beth Israel Deaconess Medical Center, Inc. | Anti-tn antibodies and uses thereof |
| IL298825A (en) * | 2020-07-02 | 2023-02-01 | Gigagen Inc | ANTI-CTLA-4 binding proteins and methods of using them |
| TW202317614A (zh) | 2021-06-07 | 2023-05-01 | 美商安進公司 | 使用岩藻糖苷酶控制糖基化蛋白的去岩藻糖基化水平 |
| US20250073323A1 (en) * | 2021-08-06 | 2025-03-06 | Anyadi, Llc | Process for producing personalized cancer immunotherapy |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US30985A (en) | 1860-12-18 | Thomas l | ||
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
| US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
| WO1991018982A1 (en) | 1990-06-05 | 1991-12-12 | Immunex Corporation | Type ii interleukin-1 receptors |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US6239328B1 (en) | 1992-10-05 | 2001-05-29 | North Carolina State University | Method for reducing expression variability of transgenes in plant cells |
| US6037525A (en) | 1996-08-01 | 2000-03-14 | North Carolina State University | Method for reducing expression variability of transgenes in plant cells |
| US6245974B1 (en) | 1997-08-06 | 2001-06-12 | North Carolina State University | Matrix attachment regions |
| US6177612B1 (en) | 1998-07-31 | 2001-01-23 | Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada | Matrix attachment regions |
| WO2000018938A1 (en) | 1998-09-29 | 2000-04-06 | Pioneer Hi-Bred International, Inc. | Mar/sar elements flanking rsyn7-driven construct |
| KR100408844B1 (ko) | 2000-07-29 | 2003-12-06 | 한국산업기술평가원 | 동물세포 발현벡터 |
| US7259010B2 (en) | 2000-12-15 | 2007-08-21 | Pangen Biotech Inc. | Expression vector for animal cell containing nuclear matrix attachment region of interferon beta |
| ATE437233T1 (de) | 2001-01-26 | 2009-08-15 | Selexis Sa | Matrix-anheftungsregionen und verfahren zu deren verwendung |
| ATE430580T1 (de) * | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| CN1938428A (zh) | 2003-11-12 | 2007-03-28 | 先灵公司 | 多基因表达的质粒系统 |
| KR20080032065A (ko) * | 2005-06-03 | 2008-04-14 | 제넨테크, 인크. | 푸코실화 수준이 조절된 항체의 생성 방법 |
| AU2006270718B2 (en) * | 2005-07-22 | 2011-07-21 | Kyowa Kirin Co., Ltd. | Genetically modified antibody composition |
| JP5298021B2 (ja) * | 2006-10-12 | 2013-09-25 | ジェネンテック， インコーポレイテッド | リンホトキシン−αに対する抗体 |
| PL2438171T3 (pl) * | 2009-06-02 | 2015-04-30 | Regeneron Pharma | Komórki z niedoborem fukozylacji |
| WO2010141855A1 (en) * | 2009-06-05 | 2010-12-09 | Momenta Pharmaceuticals, Inc. | Methods of modulating fucosylation of glycoproteins |
| AU2012226398B9 (en) * | 2011-03-06 | 2017-04-13 | Merck Serono S.A. | Low fucose cell lines and uses thereof |
| WO2013013013A2 (en) * | 2011-07-21 | 2013-01-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for producing modified glycoproteins |
| EP3036320B2 (en) * | 2013-08-19 | 2024-04-03 | Biogen MA Inc. | Control of protein glycosylation by culture medium supplementation and cell culture process parameters |
| US10752674B2 (en) * | 2014-11-15 | 2020-08-25 | Zumutor Biologics Inc. | DNA-binding domain of CRISPR system, non-fucosylated and partially fucosylated proteins, and methods thereof |
| JP6587696B2 (ja) * | 2015-05-13 | 2019-10-09 | ズムトール バイオロジクス、インコーポレイテッド | アフコシル化タンパク質、前記タンパク質を発現する細胞、及び関連する方法 |
| MX2018004831A (es) | 2015-11-02 | 2018-08-01 | Genentech Inc | Metodos para confeccionar formas fucosiladas y afucosiladas de una proteina. |
-
2016
- 2016-11-01 MX MX2018004831A patent/MX2018004831A/es unknown
- 2016-11-01 KR KR1020257011036A patent/KR20250051156A/ko active Pending
- 2016-11-01 BR BR112018007356A patent/BR112018007356A2/pt not_active Application Discontinuation
- 2016-11-01 SG SG10202103875WA patent/SG10202103875WA/en unknown
- 2016-11-01 PL PL16797693T patent/PL3371206T3/pl unknown
- 2016-11-01 SG SG11201802773RA patent/SG11201802773RA/en unknown
- 2016-11-01 WO PCT/US2016/059922 patent/WO2017079165A1/en not_active Ceased
- 2016-11-01 ES ES16797693T patent/ES2875274T3/es active Active
- 2016-11-01 CN CN201680077178.3A patent/CN108431026B/zh active Active
- 2016-11-01 EP EP16797693.5A patent/EP3371206B1/en active Active
- 2016-11-01 CN CN202310074105.0A patent/CN116731147A/zh active Pending
- 2016-11-01 CA CA2999047A patent/CA2999047A1/en active Pending
- 2016-11-01 KR KR1020187009379A patent/KR102793554B1/ko active Active
- 2016-11-01 JP JP2018522671A patent/JP6983772B2/ja active Active
- 2016-11-01 EP EP21162187.5A patent/EP3925970A1/en active Pending
- 2016-11-01 AU AU2016350732A patent/AU2016350732A1/en not_active Abandoned
-
2018
- 2018-03-15 IL IL258161A patent/IL258161B2/en unknown
- 2018-05-01 US US15/968,214 patent/US10975168B2/en active Active
-
2021
- 2021-01-13 US US17/148,456 patent/US11802165B2/en active Active
-
2022
- 2022-04-13 AU AU2022202460A patent/AU2022202460A1/en not_active Abandoned
-
2023
- 2023-09-25 US US18/474,014 patent/US12391769B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019505164A (ja) | 2019-02-28 |
| CN108431026A (zh) | 2018-08-21 |
| KR20250051156A (ko) | 2025-04-16 |
| AU2016350732A1 (en) | 2018-04-05 |
| US20180251572A1 (en) | 2018-09-06 |
| KR20180068967A (ko) | 2018-06-22 |
| ES2875274T3 (es) | 2021-11-10 |
| US12391769B2 (en) | 2025-08-19 |
| US20210214462A1 (en) | 2021-07-15 |
| US10975168B2 (en) | 2021-04-13 |
| JP6983772B2 (ja) | 2021-12-17 |
| MX2018004831A (es) | 2018-08-01 |
| CA2999047A1 (en) | 2017-05-11 |
| SG11201802773RA (en) | 2018-05-30 |
| US11802165B2 (en) | 2023-10-31 |
| CN108431026B (zh) | 2023-02-17 |
| AU2022202460A1 (en) | 2022-05-05 |
| CN116731147A (zh) | 2023-09-12 |
| EP3371206B1 (en) | 2021-04-14 |
| EP3925970A1 (en) | 2021-12-22 |
| IL258161B1 (en) | 2023-04-01 |
| KR102793554B1 (ko) | 2025-04-14 |
| IL258161B2 (en) | 2023-08-01 |
| PL3371206T3 (pl) | 2021-09-27 |
| EP3371206A1 (en) | 2018-09-12 |
| US20240158536A1 (en) | 2024-05-16 |
| SG10202103875WA (en) | 2021-06-29 |
| IL258161A (en) | 2018-05-31 |
| WO2017079165A1 (en) | 2017-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018007356A2 (pt) | métodos de produção de formas fucosiladas e não fucosiladas de uma proteína | |
| BR112018010211A2 (pt) | formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab | |
| IL254036B (en) | Perceptions in a haptic system | |
| CL2017002161A1 (es) | Jarabes de alulosa | |
| EP3360283C0 (en) | Distributed transactions with token-associated execution | |
| SG11201509284VA (en) | Anti-cxcl1, cxcl7 and cxcl8 antibodies and their applications | |
| EP3343135A4 (en) | DEFROST AND REFRIGERATOR WITH IT | |
| DK3623390T3 (da) | Kulhydrattværbinder | |
| EP3350489A4 (en) | VALVE AND COUPLING | |
| BR302014001652S1 (pt) | Configuração ornamental aplicada em processador de alimento | |
| MX2023006416A (es) | Anticuerpos, usos y metodos. | |
| IL240442A0 (en) | Stuximab with aberrant glycosylation and their uses | |
| GB201503812D0 (en) | Antibody molecules and uses thereof | |
| BR112018002382A8 (pt) | Novos anticorpos anti-gvpi humano e usos dos mesmos | |
| PT3365321T (pt) | Zwiterião de solabegron e suas utilizações | |
| AR097668A1 (es) | Colorante-polímero | |
| HUE055518T2 (hu) | Axiális-tömítésû pillangó szelepek | |
| BR112016000313A2 (pt) | Botão de válvula de gaveta, gaveta de válvula, e, válvula de gaveta | |
| NO3050465T3 (no) | Seating | |
| BR112017020037A2 (pt) | pastas minerais | |
| DE112016001950A5 (de) | Sitzgruppe | |
| TH1601002678A (th) | วิธีการสำหรับการผลิตองค์ประกอบที่มีไซแลน และวิธีการสำหรับการผลิตองค์ ประกอบที่มีกลูแคน | |
| TH1501007074B (th) | สลักเกลียวปล่อยและวิธีของการผลิตสิ่งเดียวกัน | |
| TH1601001301B (th) | ชิ้นส่วนปั๊มขึ้นรูปร้อน และวิธีการของการผลิตสิ่งเดียวกันนั้น | |
| TWM532847U (en) | Healing abutment and healing abutment assembly |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |